American Well Corporation ( (AMWL) ) has released its Q4 earnings. Here is a breakdown of the information American Well Corporation presented to its investors.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
American Well Corporation (Amwell) is a prominent provider of a SaaS-based healthcare platform that connects providers, payers, patients, and innovators to facilitate access to high-quality, cost-effective healthcare services.
In its latest earnings report, Amwell highlighted significant strides in its business operations throughout 2024, attributing advancements to collaborations like the one with Leidos, which is aiding the deployment of Amwell’s solutions across the U.S. Military Health System.
Amwell recorded a total revenue of $71.0 million for the fourth quarter of 2024 and $254.4 million for the full year, with subscription revenues and Amwell Medical Group visit revenues being notable contributors. The company reported a net loss of $212.6 million for the year, a substantial improvement from the previous year’s loss of $679.2 million, which had been impacted by goodwill impairment charges. The adjusted EBITDA for 2024 was reported at ($134.4) million, showing progress compared to ($165.4) million in 2023.
Looking ahead, the company projects its 2025 revenue to be between $250 and $260 million, alongside a forecasted adjusted EBITDA ranging from (55) million to (45) million. Amwell plans to focus on achieving positive cash flow by 2026, driven by strategic initiatives and operational efficiencies.
Amwell’s management remains optimistic about future growth prospects, leveraging strategic partnerships and continuous platform enhancements to meet stakeholder expectations and navigate the evolving healthcare landscape.
